4R Tau Drives Endolysosomal Dysfunction in VCP-Related Frontotemporal Dementia

Background: Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) share genetic and pathological features, with mutations in the valosin-containing protein (VCP) gene implicated in both disorders. However, the mechanisms linking VCP mutations to neurodegeneration remain unclear. This study investigates how 4R tau dysregulation contributes to endolysosomal and autophagy dysfunction in human neurons.
Method: Human induced pluripotent stem cell (hiPSC)-derived cortical neurons carrying VCP mutations were analyzed for endolysosomal integrity, RNA-binding protein (RBP) localization, and MAPT splicing. Antisense oligonucleotides (ASOs) were used to selectively increase 4R tau levels in control neurons to assess its impact on cellular homeostasis. Immunocytochemistry, western blotting, and proximity ligation assays were employed to evaluate tau phosphorylation, endolysosomal dysfunction, autophagic flux, and apoptosis.
Result: VCP mutations caused nuclear dissociation of fused in sarcoma (FUS) and splicing factor proline- and glutamine-rich (SFPQ), leading to aberrant MAPT pre-mRNA splicing and an increased 4R tau:3R tau ratio. These neurons exhibited enlarged endolysosomes, lysosomal membrane rupture, impaired autophagic degradation, endoplasmic reticulum stress, and apoptosis. Notably, ASO-induced 4R tau expression in control neurons replicated these pathological phenotypes, confirming 4R tau as a driver of cellular dysfunction.
Conclusion: Our findings demonstrate that 4R tau dysregulation contributes to neurodegeneration by disrupting endolysosomal and autophagic function in FTD. Targeting tau isoform balance may offer a promising therapeutic approach for VCP-related FTD.
© 2025 The Alzheimer's Association. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.